| In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) SJ McClue, D Blake, R Clarke, A Cowan, L Cummings, PM Fischer, ... International journal of cancer 102 (5), 463-468, 2002 | 477 | 2002 |
| Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin PM Fischer, NZ Zhelev, S Wang, JE Melville, R Fåhraeus, DP Lane The Journal of peptide research 55 (2), 163-172, 2000 | 221 | 2000 |
| 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity S Wang, C Meades, G Wood, A Osnowski, S Anderson, R Yuill, M Thomas, ... Journal of medicinal chemistry 47 (7), 1662-1675, 2004 | 197 | 2004 |
| Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop SY Wu, I McNae, G Kontopidis, SJ McClue, C McInnes, KJ Stewart, ... Structure 11 (4), 399-410, 2003 | 159 | 2003 |
| New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure− activity relationships J Šarek, J Klinot, P Džubák, E Klinotová, V Nosková, V Křeček, ... Journal of medicinal chemistry 46 (25), 5402-5415, 2003 | 129 | 2003 |
| Bioluminescent imaging of Cdk2 inhibition in vivo GJ Zhang, M Safran, W Wei, E Sorensen, P Lassota, N Zhelev, ... Nature medicine 10 (6), 643-648, 2004 | 119 | 2004 |
| A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics DI Zheleva, NZ Zhelev, PM Fischer, SV Duff, E Warbrick, DG Blake, ... Biochemistry 39 (25), 7388-7397, 2000 | 102 | 2000 |
| Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A DI Zheleva, C McInnes, AL Gavine, NZ Zhelev, PM Fischer, DP Lane The Journal of peptide research 60 (5), 257-270, 2002 | 85 | 2002 |
| Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design G Kontopidis, C McInnes, SR Pandalaneni, I McNae, D Gibson, M Mezna, ... Chemistry & biology 13 (2), 201-211, 2006 | 74 | 2006 |
| Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance HS Khalil, V Mitev, T Vlaykova, L Cavicchi, N Zhelev Journal of biotechnology 202, 40-49, 2015 | 70 | 2015 |
| Saponins from Tribulus terrestris L. Are Less Toxic for Normal Human Fibroblasts than for Many Cancer Lines: Influence on Apoptosis and Proliferation VK Neychev, E Nikolova, N Zhelev, VI Mitev Experimental Biology and Medicine 232 (1), 126-133, 2007 | 66 | 2007 |
| Peptidomimetic Design of CDK Inhibitors Targeting theRecruitment Site of the Cyclin Subunit C McInnes, MJ Andrews, DI Zheleva, DP Lane, PM Fischer Current Medicinal Chemistry-Anti-Cancer Agents 3 (1), 57-69, 2003 | 65 | 2003 |
| Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. H Kovárová, M Hajdúch, G Korinkova, P Halada, S Krupickova, ... Electrophoresis 21 (17), 3757-3764, 2000 | 58 | 2000 |
| A mitogen‐and anisomycin‐stimulated kinase phosphorylates HMG‐14 in its basic amino‐terminal domain in vivo and on isolated mononucleosomes. MJ Barratt, CA Hazzalin, N Zhelev, LC Mahadevan The EMBO Journal 13 (19), 4524-4535, 1994 | 58 | 1994 |
| Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction E Kardalinou, N Zhelev, CA Hazzalin, LC Mahadevan Molecular and cellular biology, 1994 | 56 | 1994 |
| LC (1994) Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction E Kardalinou, N Zhelev, CAYM HAZZALIN Mol. Cell. Biol 14, 1066-1074, 0 | 56* | |
| DNA damage and mutation. Types of DNA damage S Chakarov, R Petkova, GC Russev, N Zhelev BioDiscovery 11, e8957, 2014 | 48 | 2014 |
| Targeting ATM pathway for therapeutic intervention in cancer HS Khalil, H Tummala, S Chakarov, N Zhelev, DP Lane Biodiscovery 1, e8920, 2012 | 46 | 2012 |
| Carrier based drug delivery system PM Fischer, S Wang, N Zhelev US Patent 6,472,507, 2002 | 42* | 2002 |
| The role of modelling in identifying drug targets for diseases of the cell cycle RG Clyde, JL Bown, TR Hupp, N Zhelev, JW Crawford Journal of The Royal Society Interface 3 (10), 617-627, 2006 | 36 | 2006 |
Hilal Shahid KhalilMS| PhD | MLS (ASCP)Verified email at bhmcny.org
